Compare The Vita Coco Company Inc (COCO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Vita Coco Company Inc vs Novo Nordisk A/S — how do they compare? The Vita Coco Company Inc trades at $64.43 (market cap $3.63B), while Novo Nordisk A/S trades at $46.76 (market cap $207.31B). The key difference: Novo Nordisk A/S is far larger — about 57.1× The Vita Coco Company Inc's market cap, and Novo Nordisk A/S pays a 3.76% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| COCO | NVO | |
|---|---|---|
Market Cap | $3.63B | $207.31B |
Sector | Technology | Health |
52-Week High | $84.02 | $63.98 |
52-Week Low | $32.37 | $35.29 |
Enterprise Value | $3.37B | $222.02B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Vita Coco Company (COCO) trades at $62.25, down 2.92% over 24 hours, with a bullish technical signal driven by oversold RSI readings and support near $62. Fundamentally, Q2 2026 earnings beat expectations with EPS of $0.82 versus $0.56 estimated, while revenue grew 28% year-over-year to $216 million. The company raised full-year 2026 guidance, reflecting strong demand and the Copra acquisition.
Outlook remains positive with 60% analyst buy ratings and an $80.67 consensus price target, implying ~30% upside. Key risks include margin pressure from rising costs and capacity constraints. Growth catalysts include international expansion and health-focused innovation in the beverage sector.
Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.
Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
